Literature DB >> 34990726

Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.

Amar U Kishan1, Nicholas Marco2, Melanie-Birte Schulz-Jaavall3, Michael L Steinberg4, Phuoc T Tran5, Jesus E Juarez4, Audrey Dang4, Donatello Telesca2, Wolfgang A Lilleby3, Joanne B Weidhaas4.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was to determine whether single nucleotide polymorphisms disrupting microRNA targets (mirSNPs) can serve as predictive biomarkers for toxicity after radiotherapy for prostate cancer and whether these may be differentially predictive depending on radiation fractionation.
MATERIALS AND METHODS: We identified 201 men treated with two forms of definitive radiotherapy for prostate cancer at two institutions: 108 men received conventionally-fractionated radiotherapy (CF-RT) and 93 received stereotactic body radiotherapy (SBRT). Germline DNA was evaluated for the presence of functional mirSNPs. Random forest, boosted trees and elastic net models were developed to predict late grade ≥2 GU toxicity by the RTOG scale.
RESULTS: The crude incidence of late grade ≥2 GU toxicity was 16% after CF-RT and 15% after SBRT. An elastic net model based on 22 mirSNPs differentiated CF-RT patients at high risk (71.5%) versus low risk (7.5%) for toxicity, with an area under the curve (AUC) values of 0.76-0.81. An elastic net model based on 32 mirSNPs differentiated SBRT patients at high risk (64.7%) versus low risk (3.9%) for toxicity, with an area under the curve (AUC) values of 0.81-0.87. These models were specific to treatment type delivered. Prospective studies are warranted to further validate these results.
CONCLUSION: Predictive models using germline mirSNPs have high accuracy for predicting late grade ≥2 GU toxicity after either CF-RT or SBRT, and are unique for each treatment, suggesting that germline predictors of late radiation sensitivity are fractionation-dependent. Prospective studies are warranted to further validate these results.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Germline; IMRT; Prostate; SBRT; SNPs; Toxicity

Mesh:

Substances:

Year:  2022        PMID: 34990726      PMCID: PMC8979583          DOI: 10.1016/j.radonc.2021.12.040

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.901


  27 in total

1.  The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans.

Authors:  B J Reinhart; F J Slack; M Basson; A E Pasquinelli; J C Bettinger; A E Rougvie; H R Horvitz; G Ruvkun
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

Review 2.  How should we assess patient-reported outcomes in the onco-hematology clinic?

Authors:  Laura Cannella; Fabio Efficace; Johannes Giesinger
Journal:  Curr Opin Support Palliat Care       Date:  2018-12       Impact factor: 2.302

3.  Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.

Authors:  Robert M Meier; Daniel A Bloch; Cristian Cotrutz; Alan C Beckman; George T Henning; Shermian A Woodhouse; Shirnett K Williamson; Najeeb Mohideen; John J Dombrowski; Robert L Hong; David G Brachman; Patrick W Linson; Irving D Kaplan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-01       Impact factor: 7.038

4.  Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Authors:  Jeff M Michalski; Yan Yan; Deborah Watkins-Bruner; Walter R Bosch; Kathryn Winter; James M Galvin; Jean-Paul Bahary; Gerard C Morton; Matthew B Parliament; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-08       Impact factor: 7.038

5.  Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study.

Authors:  Matthew G Parry; Arunan Sujenthiran; Thomas E Cowling; Julie Nossiter; Paul Cathcart; Noel W Clarke; Heather Payne; Jan van der Meulen; Ajay Aggarwal
Journal:  J Clin Oncol       Date:  2019-06-04       Impact factor: 44.544

6.  Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy.

Authors:  Sangkyu Lee; Sarah Kerns; Harry Ostrer; Barry Rosenstein; Joseph O Deasy; Jung Hun Oh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-31       Impact factor: 7.038

7.  Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Authors:  Christian Nicolaj Andreassen; Barry S Rosenstein; Sarah L Kerns; Harry Ostrer; Dirk De Ruysscher; Jamie A Cesaretti; Gillian C Barnett; Alison M Dunning; Leila Dorling; Catharine M L West; Neil G Burnet; Rebecca Elliott; Charlotte Coles; Emma Hall; Laura Fachal; Ana Vega; Antonio Gómez-Caamaño; Christopher J Talbot; R Paul Symonds; Kim De Ruyck; Hubert Thierens; Piet Ost; Jenny Chang-Claude; Petra Seibold; Odilia Popanda; Marie Overgaard; David Dearnaley; Matthew R Sydes; David Azria; Christine Anne Koch; Matthew Parliament; Michael Blackshaw; Michael Sia; Maria J Fuentes-Raspall; Teresa Ramon Y Cajal; Agustin Barnadas; Danny Vesprini; Sara Gutiérrez-Enríquez; Meritxell Mollà; Orland Díez; John R Yarnold; Jens Overgaard; Søren M Bentzen; Jan Alsner
Journal:  Radiother Oncol       Date:  2016-07-18       Impact factor: 6.280

Review 8.  Patient-reported outcomes in cancer care - hearing the patient voice at greater volume.

Authors:  Thomas W LeBlanc; Amy P Abernethy
Journal:  Nat Rev Clin Oncol       Date:  2017-10-04       Impact factor: 66.675

9.  Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.

Authors:  Justin G Trogdon; Aaron D Falchook; Ramsankar Basak; William R Carpenter; Ronald C Chen
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

10.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Authors:  Amar U Kishan; Audrey Dang; Alan J Katz; Constantine A Mantz; Sean P Collins; Nima Aghdam; Fang-I Chu; Irving D Kaplan; Limor Appelbaum; Donald B Fuller; Robert M Meier; D Andrew Loblaw; Patrick Cheung; Huong T Pham; Narek Shaverdian; Naomi Jiang; Ye Yuan; Hilary Bagshaw; Nicolas Prionas; Mark K Buyyounouski; Daniel E Spratt; Patrick W Linson; Robert L Hong; Nicholas G Nickols; Michael L Steinberg; Patrick A Kupelian; Christopher R King
Journal:  JAMA Netw Open       Date:  2019-02-01
View more
  2 in total

Review 1.  Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.

Authors:  Zsuzsanna Gaál
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

2.  A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome.

Authors:  Una Ryg; Therese Seierstad; Line Brennhaug Nilsen; Taran Paulsen Hellebust; Linda Holth Djupvik; Hilde Gustafson; Jørgen Hydal; Amar U Kishan; Knut Håkon Hole; Wolfgang Lilleby
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.